MESO SEC Filings: 8-K, 10-Q, S-3 & 424B – Mesoblast

Financials

TYPE

HEADLINE

FILED AT

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Aug 27, 2026

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Aug 29, 2025

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Aug 29, 2024

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Aug 30, 2023

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Aug 31, 2022

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Aug 31, 2021

News

TYPE

HEADLINE

FILED AT

6-K

Mesoblast Limited Announces Cessation of Director Philip R. Krause

Nov 2, 2026

6-K

Mesoblast Reports Q1 FY2027 Activity Report and Appendix 4C Cash Flow

Oct 29, 2026

6-K

Mesoblast Reports 44% Increase in Ryoncil® Net Revenue and 85% Improvement in Net Operating Cash Spend in First Fiscal Quarter

Oct 15, 2026

6-K

Mesoblast Limited Files Forms Regarding Security Cessation, Unquoted Equity, and Quotation of Securities

Oct 15, 2026

6-K

Mesoblast Limited Reports Fiscal Year 2026 Financial Results and Commercial Success of RYONCIL

Oct 13, 2026

6-K

Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product

Sep 23, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Jan 14, 2026

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Feb 12, 2025

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Dec 27, 2024

424B3

58,000,000 Ordinary Shares represented by 5,800,000American Depositary Shares

Apr 26, 2024

424B3

18,188,175 Ordinary Shares represented by 3,637,635 American Depositary Shares

May 26, 2023

424B3

2,275,000 Ordinary Shares represented by 455,000 American Depositary Shares

Apr 4, 2023

Registrations

TYPE

HEADLINE

FILED AT

F-3ASR

Form F-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Dec 31, 2025

F-3

Form F-3 - Registration statement by foreign private issuers

Dec 30, 2025

F-3/A

Form F-3/A - Registration statement by foreign private issuers: [Amend]

Feb 6, 2025

F-3

Form F-3 - Registration statement by foreign private issuers

Feb 5, 2025

F-3/A

Form F-3/A - Registration statement by foreign private issuers: [Amend]

Dec 23, 2024

F-3

Form F-3 - Registration statement by foreign private issuers

Dec 13, 2024

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

OBRIEN JAMES MICHAEL (Reporting)

Jul 9, 2026

COBLEY LYNETTE ELIZABETH (Reporting)

Apr 29, 2026

George Gregory (Reporting)

Apr 13, 2026

George Gregory (Reporting)

Apr 10, 2026

BURNS WILLIAM MURRAY (Reporting)

Apr 1, 2026

Itescu Silviu (Reporting)

Apr 1, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jan 15, 2026

CORRESP

Form CORRESP - Correspondence

Jan 12, 2026

LETTER

Form UPLOAD - SEC-generated letter

Jan 5, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Feb 13, 2025

CORRESP

Form CORRESP - Correspondence

Feb 10, 2025

LETTER

Form UPLOAD - SEC-generated letter

Feb 7, 2025

Mesoblast Limited MESO · SEC Filings